JULIAN BAKER Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JULIAN BAKER.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JULIAN BAKER. JULIAN BAKER is Director in INCYTE CORP ($INCY) and Director in IDERA PHARMACEUTICALS, INC. ($IDRA) and Director in SYNAGEVA BIOPHARMA CORP ($GEVA).
Latest Insider Trading Transactions of JULIAN BAKER
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, IDRA, INCY, GEVA
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | D | 51.76 | 6,050,000 | 313,135,900 | 0 | |
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | D | 51.76 | 5,674,000 | 293,674,892 | 0 | |
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | D | 51.76 | 243,450,000 | 12,600,485,100 | 0 | |
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | D | 51.76 | 228,326,000 | 11,817,697,108 | 0 | |
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | D | 51.76 | 25,000,000 | 1,293,950,000 | 0 | |
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | D | 51.76 | 25,000,000 | 1,293,950,000 | 0 | |
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 0.00 | 121,672 | 0 | 767,095 | 645.4 K to 767.1 K (+18.85 %) |
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 0.00 | 111,514 | 0 | 645,423 | 533.9 K to 645.4 K (+20.89 %) |
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 0.00 | 4,896,067 | 0 | 29,141,653 | 24.2 M to 29.1 M (+20.19 %) |
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 0.00 | 4,487,412 | 0 | 24,245,586 | 19.8 M to 24.2 M (+22.71 %) |
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 0.00 | 502,779 | 0 | 4,353,957 | 3.9 M to 4.4 M (+13.06 %) |
| Feb 22 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 0.00 | 491,338 | 0 | 3,851,178 | 3.4 M to 3.9 M (+14.62 %) |
| Jan 05 2017 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 1.50 | 14,169 | 21,254 | 125,179 | 111 K to 125.2 K (+12.76 %) |
| Jan 05 2017 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 1.50 | 14,169 | 21,254 | 9,323,502 | 9.3 M to 9.3 M (+0.15 %) |
| Jan 05 2017 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 1.50 | 14,169 | 21,254 | 1,017,950 | 1 M to 1 M (+1.41 %) |
| Jan 04 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 100.27 | 189 | 18,951 | 533,909 | 533.7 K to 533.9 K (+0.04 %) |
| Jan 04 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 100.27 | 189 | 18,951 | 19,758,174 | 19.8 M to 19.8 M (0.00 %) |
| Jan 04 2017 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 100.27 | 189 | 18,951 | 3,359,840 | 3.4 M to 3.4 M (+0.01 %) |
| Oct 11 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Buy | P | 2.00 | 2,928,596 | 5,857,192 | 9,309,333 | 6.4 M to 9.3 M (+45.90 %) |
| Oct 11 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Buy | P | 2.00 | 321,404 | 642,808 | 1,003,781 | 682.4 K to 1 M (+47.10 %) |
| Oct 05 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 2.56 | 8,299 | 21,245 | 111,010 | 102.7 K to 111 K (+8.08 %) |
| Oct 05 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 2.56 | 8,299 | 21,245 | 6,380,737 | 6.4 M to 6.4 M (+0.13 %) |
| Oct 05 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 2.56 | 8,299 | 21,245 | 682,377 | 674.1 K to 682.4 K (+1.23 %) |
| Oct 04 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 94.29 | 201 | 18,952 | 533,720 | 533.5 K to 533.7 K (+0.04 %) |
| Oct 04 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 94.29 | 201 | 18,952 | 19,757,985 | 19.8 M to 19.8 M (0.00 %) |
| Oct 04 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 94.29 | 201 | 18,952 | 3,359,651 | 3.4 M to 3.4 M (+0.01 %) |
| Jul 06 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 1.63 | 13,038 | 21,252 | 102,711 | 89.7 K to 102.7 K (+14.54 %) |
| Jul 06 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 1.63 | 13,038 | 21,252 | 6,372,438 | 6.4 M to 6.4 M (+0.21 %) |
| Jul 06 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 1.63 | 13,038 | 21,252 | 674,078 | 661 K to 674.1 K (+1.97 %) |
| Jul 05 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 79.98 | 237 | 18,955 | 533,519 | 533.3 K to 533.5 K (+0.04 %) |
| Jul 05 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 79.98 | 237 | 18,955 | 19,757,784 | 19.8 M to 19.8 M (0.00 %) |
| Jul 05 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 79.98 | 237 | 18,955 | 3,359,450 | 3.4 M to 3.4 M (+0.01 %) |
| Jun 15 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Option Exercise | A | 1.44 | 70,000 | 100,800 | 70,000 | |
| May 31 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | A | 84.53 | 15,000 | 1,267,950 | 15,000 | |
| Apr 04 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 72.47 | 262 | 18,987 | 533,282 | 533 K to 533.3 K (+0.05 %) |
| Apr 04 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 72.47 | 262 | 18,987 | 19,757,547 | 19.8 M to 19.8 M (0.00 %) |
| Apr 04 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 72.47 | 262 | 18,987 | 3,359,213 | 3.4 M to 3.4 M (+0.01 %) |
| Apr 05 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 1.97 | 10,788 | 21,252 | 89,673 | 78.9 K to 89.7 K (+13.68 %) |
| Apr 05 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 1.97 | 10,788 | 21,252 | 6,359,400 | 6.3 M to 6.4 M (+0.17 %) |
| Apr 05 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 1.97 | 10,788 | 21,252 | 661,040 | 650.3 K to 661 K (+1.66 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | M | 3.86 | 20,000 | 77,200 | 0 | |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | M | 3.86 | 20,000 | 77,200 | 0 | |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | M | 3.86 | 20,000 | 77,200 | 0 | |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 62.59 | 90,179 | 5,644,024 | 19,757,285 | 19.7 M to 19.8 M (+0.46 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 62.59 | 9,821 | 614,666 | 3,358,951 | 3.3 M to 3.4 M (+0.29 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 61.38 | 127,964 | 7,854,149 | 19,667,106 | 19.5 M to 19.7 M (+0.65 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 61.38 | 13,936 | 855,361 | 3,349,130 | 3.3 M to 3.3 M (+0.42 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 61.03 | 24,431 | 1,490,975 | 19,539,142 | 19.5 M to 19.5 M (+0.13 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 61.03 | 2,660 | 162,334 | 3,335,194 | 3.3 M to 3.3 M (+0.08 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 60.95 | 20,659 | 1,259,178 | 19,514,711 | 19.5 M to 19.5 M (+0.11 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 60.95 | 2,250 | 137,139 | 3,332,534 | 3.3 M to 3.3 M (+0.07 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 60.85 | 97,484 | 5,931,960 | 19,494,052 | 19.4 M to 19.5 M (+0.50 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 60.85 | 10,616 | 645,990 | 3,330,284 | 3.3 M to 3.3 M (+0.32 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | M | 3.86 | 20,000 | 77,200 | 533,020 | 513 K to 533 K (+3.90 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | M | 3.86 | 20,000 | 77,200 | 19,396,568 | 19.4 M to 19.4 M (+0.10 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | M | 3.86 | 20,000 | 77,200 | 3,319,668 | 3.3 M to 3.3 M (+0.61 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 65.29 | 1,182 | 77,176 | 19,376,568 | 19.4 M to 19.4 M (+0.01 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 65.29 | 129 | 8,423 | 3,299,668 | 3.3 M to 3.3 M (0.00 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 65.80 | 179,176 | 11,789,387 | 19,375,386 | 19.2 M to 19.4 M (+0.93 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 65.80 | 19,513 | 1,283,912 | 3,299,539 | 3.3 M to 3.3 M (+0.59 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 67.15 | 180,358 | 12,110,607 | 19,196,210 | 19 M to 19.2 M (+0.95 %) |
| Mar 17 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 67.15 | 19,642 | 1,318,913 | 3,280,026 | 3.3 M to 3.3 M (+0.60 %) |
| Feb 26 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 74.00 | 6,022 | 445,628 | 19,015,852 | 19 M to 19 M (+0.03 %) |
| Feb 26 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 74.00 | 678 | 50,172 | 3,260,384 | 3.3 M to 3.3 M (+0.02 %) |
| Feb 26 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 69.70 | 20,492 | 1,428,282 | 19,009,830 | 19 M to 19 M (+0.11 %) |
| Feb 26 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 69.70 | 2,308 | 160,866 | 3,259,706 | 3.3 M to 3.3 M (+0.07 %) |
| Feb 26 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 70.51 | 23,157 | 1,632,684 | 18,989,338 | 19 M to 19 M (+0.12 %) |
| Feb 26 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 70.51 | 2,608 | 183,877 | 3,257,398 | 3.3 M to 3.3 M (+0.08 %) |
| Feb 26 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 71.96 | 8,111 | 583,702 | 18,966,181 | 19 M to 19 M (+0.04 %) |
| Feb 26 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 71.96 | 914 | 65,775 | 3,254,790 | 3.3 M to 3.3 M (+0.03 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 69.45 | 15,187 | 1,054,742 | 18,958,070 | 18.9 M to 19 M (+0.08 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 69.45 | 1,651 | 114,662 | 3,253,876 | 3.3 M to 3.3 M (+0.05 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 70.86 | 8,250 | 584,597 | 18,942,883 | 18.9 M to 18.9 M (+0.04 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 70.86 | 897 | 63,562 | 3,252,225 | 3.3 M to 3.3 M (+0.03 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 69.54 | 67,373 | 4,684,923 | 18,934,633 | 18.9 M to 18.9 M (+0.36 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 69.54 | 7,326 | 509,429 | 3,251,328 | 3.2 M to 3.3 M (+0.23 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 70.21 | 124,057 | 8,710,228 | 18,867,260 | 18.7 M to 18.9 M (+0.66 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 70.21 | 13,490 | 947,153 | 3,244,002 | 3.2 M to 3.2 M (+0.42 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 71.10 | 397,079 | 28,233,945 | 18,743,203 | 18.3 M to 18.7 M (+2.16 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 71.10 | 43,178 | 3,070,133 | 3,230,512 | 3.2 M to 3.2 M (+1.35 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 67.94 | 149,927 | 10,186,595 | 18,346,124 | 18.2 M to 18.3 M (+0.82 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 67.94 | 16,450 | 1,117,674 | 3,187,334 | 3.2 M to 3.2 M (+0.52 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 63.98 | 38,117 | 2,438,547 | 18,196,197 | 18.2 M to 18.2 M (+0.21 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 63.98 | 4,183 | 267,609 | 3,170,884 | 3.2 M to 3.2 M (+0.13 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 64.87 | 168,055 | 10,902,350 | 18,158,080 | 18 M to 18.2 M (+0.93 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 64.87 | 18,441 | 1,196,336 | 3,166,701 | 3.1 M to 3.2 M (+0.59 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 65.80 | 541,340 | 35,621,958 | 17,990,025 | 17.4 M to 18 M (+3.10 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 65.80 | 59,401 | 3,908,782 | 3,148,260 | 3.1 M to 3.1 M (+1.92 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 66.68 | 49,021 | 3,268,823 | 17,448,685 | 17.4 M to 17.4 M (+0.28 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 66.68 | 5,379 | 358,683 | 3,088,859 | 3.1 M to 3.1 M (+0.17 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 67.68 | 72,894 | 4,933,706 | 17,399,664 | 17.3 M to 17.4 M (+0.42 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 67.68 | 7,999 | 541,399 | 3,083,480 | 3.1 M to 3.1 M (+0.26 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 60.85 | 6,939 | 422,220 | 17,326,770 | 17.3 M to 17.3 M (+0.04 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 60.85 | 761 | 46,305 | 3,075,481 | 3.1 M to 3.1 M (+0.02 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 61.73 | 57,865 | 3,572,047 | 17,319,831 | 17.3 M to 17.3 M (+0.34 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 61.73 | 6,349 | 391,928 | 3,074,720 | 3.1 M to 3.1 M (+0.21 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 58.13 | 136,793 | 7,952,133 | 17,261,966 | 17.1 M to 17.3 M (+0.80 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 58.13 | 15,010 | 872,570 | 3,068,371 | 3.1 M to 3.1 M (+0.49 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 59.01 | 114,908 | 6,780,526 | 17,125,173 | 17 M to 17.1 M (+0.68 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 59.01 | 12,609 | 744,036 | 3,053,361 | 3 M to 3.1 M (+0.41 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 60.40 | 65,309 | 3,944,513 | 17,010,265 | 16.9 M to 17 M (+0.39 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 60.40 | 7,166 | 432,810 | 3,040,752 | 3 M to 3 M (+0.24 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 61.40 | 113,546 | 6,971,475 | 16,944,956 | 16.8 M to 16.9 M (+0.67 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 61.40 | 12,459 | 764,955 | 3,033,586 | 3 M to 3 M (+0.41 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 62.56 | 289,755 | 18,126,986 | 16,831,410 | 16.5 M to 16.8 M (+1.75 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 62.56 | 31,795 | 1,989,086 | 3,021,127 | 3 M to 3 M (+1.06 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 63.37 | 176,647 | 11,194,368 | 16,541,655 | 16.4 M to 16.5 M (+1.08 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 63.37 | 19,383 | 1,228,328 | 2,989,332 | 3 M to 3 M (+0.65 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 64.46 | 235,734 | 15,195,814 | 16,365,008 | 16.1 M to 16.4 M (+1.46 %) |
| Feb 16 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | P | 64.46 | 25,869 | 1,667,560 | 2,969,949 | 2.9 M to 3 M (+0.88 %) |
| Jan 06 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 3.00 | 7,082 | 21,246 | 78,885 | 71.8 K to 78.9 K (+9.86 %) |
| Jan 06 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 3.00 | 7,082 | 21,246 | 6,348,612 | 6.3 M to 6.3 M (+0.11 %) |
| Jan 06 2016 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 3.00 | 7,082 | 21,246 | 650,252 | 643.2 K to 650.3 K (+1.10 %) |
| Jan 05 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 108.45 | 175 | 18,979 | 513,020 | 512.8 K to 513 K (+0.03 %) |
| Jan 05 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 108.45 | 175 | 18,979 | 16,129,274 | 16.1 M to 16.1 M (0.00 %) |
| Jan 05 2016 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 108.45 | 175 | 18,979 | 2,944,080 | 2.9 M to 2.9 M (+0.01 %) |
| Oct 05 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 110.33 | 172 | 18,977 | 512,845 | 512.7 K to 512.8 K (+0.03 %) |
| Oct 05 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 110.33 | 172 | 18,977 | 16,129,099 | 16.1 M to 16.1 M (0.00 %) |
| Oct 05 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 110.33 | 172 | 18,977 | 2,943,905 | 2.9 M to 2.9 M (+0.01 %) |
| Oct 05 2015 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 3.06 | 6,945 | 21,252 | 71,803 | 64.9 K to 71.8 K (+10.71 %) |
| Oct 05 2015 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 3.06 | 6,945 | 21,252 | 6,341,530 | 6.3 M to 6.3 M (+0.11 %) |
| Oct 05 2015 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 3.06 | 6,945 | 21,252 | 643,170 | 636.2 K to 643.2 K (+1.09 %) |
| Sep 18 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | M | 8.78 | 892,000 | 7,827,300 | 0 | |
| Sep 18 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | M | 8.78 | 31,967,000 | 280,510,425 | 0 | |
| Sep 18 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | M | 8.78 | 7,587,000 | 66,575,925 | 0 | |
| Sep 18 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | M | 8.78 | 65,000 | 570,375 | 0 | |
| Sep 18 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Option Exercise | M | 8.78 | 64,000 | 561,600 | 0 | |
| Sep 18 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | M | 0.00 | 101,652 | 0 | 512,673 | 411 K to 512.7 K (+24.73 %) |
| Sep 18 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | M | 0.00 | 3,642,962 | 0 | 16,128,927 | 12.5 M to 16.1 M (+29.18 %) |
| Sep 18 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | M | 0.00 | 864,614 | 0 | 2,943,733 | 2.1 M to 2.9 M (+41.59 %) |
| Sep 18 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | M | 0.00 | 7,406 | 0 | 61,049 | 53.6 K to 61 K (+13.81 %) |
| Sep 18 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Buy | M | 0.00 | 7,292 | 0 | 58,632 | 51.3 K to 58.6 K (+14.20 %) |
| Jul 06 2015 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 3.66 | 5,260 | 19,252 | 64,858 | 59.6 K to 64.9 K (+8.83 %) |
| Jul 06 2015 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 3.66 | 5,260 | 19,252 | 6,334,585 | 6.3 M to 6.3 M (+0.08 %) |
| Jul 06 2015 | IDRA | IDERA PHARMACEUTIC ... | BAKER JULIAN | Director | Grant | A | 3.66 | 5,260 | 19,252 | 636,225 | 631 K to 636.2 K (+0.83 %) |
| Jul 06 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 104.21 | 182 | 18,966 | 411,021 | 410.8 K to 411 K (+0.04 %) |
| Jul 06 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 104.21 | 182 | 18,966 | 12,485,965 | 12.5 M to 12.5 M (0.00 %) |
| Jul 06 2015 | INCY | INCYTE CORP | BAKER JULIAN | Director | Grant | A | 104.21 | 182 | 18,966 | 2,079,119 | 2.1 M to 2.1 M (+0.01 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Buy | J | 0.00 | 21,196 | 0 | 100,523 | 79.3 K to 100.5 K (+26.72 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Sell | J | 0.00 | 211,614 | 0 | 12,250 | 223.9 K to 12.3 K (-94.53 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Buy | J | 0.00 | 497 | 0 | 79,327 | 78.8 K to 79.3 K (+0.63 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Sell | J | 0.00 | 100,490 | 0 | 12,250 | 112.7 K to 12.3 K (-89.13 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Buy | J | 0.00 | 40,449 | 0 | 78,830 | 38.4 K to 78.8 K (+105.39 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Sell | J | 0.00 | 1,068,128 | 0 | 680,187 | 1.7 M to 680.2 K (-61.09 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Buy | J | 0.00 | 5,543 | 0 | 38,381 | 32.8 K to 38.4 K (+16.88 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Sell | J | 0.00 | 55,479 | 0 | 12,250 | 67.7 K to 12.3 K (-81.91 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Buy | J | 0.00 | 12,500 | 0 | 32,838 | 20.3 K to 32.8 K (+61.46 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Sell | J | 0.00 | 165,213 | 0 | 12,250 | 177.5 K to 12.3 K (-93.10 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Buy | J | 0.00 | 19,318 | 0 | 20,338 | 1 K to 20.3 K (+1,893.92 %) |
| Jun 22 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Sell | J | 0.00 | 206,800 | 0 | 12,250 | 219.1 K to 12.3 K (-94.41 %) |